Next Investors logo grey

Planting underway at CropLogic’s CBD producing Trial Hemp Farm

Published 25-JUN-2019 11:04 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

After completing site preparations and seed germination, CropLogic Limited (ASX:CLI) has commenced planting at its 500 acre Trial Hemp Farm in Central Oregon.

The Trial Hemp Farm, operated by CLI’s wholly owned subsidiary LogicalCropping, will crop approximately 500 acres of CBD producing hemp over five sites using two different irrigation methods: aerial spraying circular pivot methodology and drip tape and mulch plastic methodology.

LogicalCropping as a source of premium CBD producing biomass and the planting process is supported with CLI agronomy and AgTech expertise.

Drip tape and mulch plastic methodology is a common irrigation method used for hemp on small scale farms.

The process of installing this irrigation system is an intricate one and involved initially laying drip tape and mulch plastic and then connecting each line of drip tape to a high-pressure hose and the irrigation pump.

Seedlings are then planted by a machine poking a hole in the mulch plastic, providing an allocation of water and then a worker planting the plant.

Although this process is intricate compared to other methods it is said to have a positive impact on yield in both plant volume and CBD percentage.

Drip Tape and Mulch Plastic being laid at field 'Hercules' (image taken with drone).Seedlings being planted on field 'Aries' into drip tape and mulch plastic.

CLI will use its agronomy expertise and suite of AgTech products such as CropLogic RealTime and CropLogic Aerial Imagery to develop and optimise an evidence base this season by comparing yield rates with fields using pivot irrigation methodology.

CLI CEO James Cooper-Jones said, “A dedicated and experienced management team, with years of cropping and plant science experience provided by CropLogic, has seen LogicalCropping once again achieve a key milestone on time.

“These developments have not gone unnoticed. Interest in CropLogic’s farm management, agronomy and AgTech expertise and LogicalCropping as potential source of premium CBD producing hemp biomass mass continues to grow.”

Is CLI undervalued?

The $18.3 million capped CLI, is an award-winning global agricultural technology company providing digital agricultural cutting edge technology for decision support. After launching its product into Washington State, USA in 2017, CLI is servicing a significant portion of horticultural growers in this region, with a market share as high as 30% in some crops.

Following significant growth (2017-2018) in Washington State and Northern Oregon, in 2018, CropLogic expanded into the Idaho market.

CropLogic offers growers of irrigated crops with digital agricultural technology expertise based upon scientific research and delivered with cutting edge technology – science, agronomy and technology interwoven into an expert system for decision support.

CLI draws comparisons with fellow Australian grower, the $682 million Select Harvests (ASX:SHV), which generated earnings (EBIT) of $34.9 million in 2018, while carrying $70.8 million debt, as at June 30.

Comparisons with Elixinol Global (ASX:EXL; OTCQX:ELLXF) are also apt.

Read: Hemp demand sees Elixinol fly high with outstanding revenue growth

Like CLI, Elixinol has operations in the US. It is a manufacturer and global distributor of hemp dietary supplement and skincare products.

EXL has a $533 million market cap after the company's shares surged earlier this year on the back of outstanding year-on-year revenue growth.

CLI is also looking to capitalise on the changing landscape in the US.

The data it generates from farming industrial hemp at the trial farm this season will see it better poised to support the US hemp market — which is projected to triple to $22 billion by 2022 — with agronomic and technical support.

Furthermore, the number of licensed growers in Oregon climbed from 13 to 584 following the introduction of the 2018 US federal Farm Bill, and hemp acreage has swelled from essentially zero to more than 11,000 acres, and is likely to increase further still.

Considering at how Elixinol shareholders reacted to its year-on-year revenue growth, and that CLI's pre-tax profit in FY2020 should be about three times its current EV of $13 million, CLI looks to be in a strong position.

Notwithstanding, the loss reflected on its bottom line, notably due to ASX-listing expenses, the company is generating revenues that are expected to grow substantially.

As Trevor Hoey pointed out in a previous article, "Imagine snapping up CropLogic for $40 million less tax and completely recouping your investment in the space of 12 months - these are the sums that potential suitors will be doing in the relatively near-term".

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.